Accolade Past Earnings Performance
Past criteria checks 0/6
Accolade's earnings have been declining at an average annual rate of -17.4%, while the Healthcare industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 24.8% per year.
Key information
-17.4%
Earnings growth rate
27.7%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 24.8% |
Return on equity | -57.6% |
Net Margin | -40.4% |
Last Earnings Update | 30 Nov 2024 |
Recent past performance updates
Recent updates
Accolade: A GARP Stock Trading Well Under 1X Revenues
Dec 05Accolade: Consider Both Short-Term Revenue Outlook And Rumored Takeover
Sep 09Slammed 50% Accolade, Inc. (NASDAQ:ACCD) Screens Well Here But There Might Be A Catch
Jun 29Accolade: Mixed Guidance (Rating Downgrade)
Jun 28Does Accolade (NASDAQ:ACCD) Have A Healthy Balance Sheet?
Jun 05Accolade: Staying Bullish On Favorable Developments
Apr 05Why We're Not Concerned About Accolade, Inc.'s (NASDAQ:ACCD) Share Price
Feb 17Accolade: Remain Confident That FY25 Guided Growth Is Achievable
Jan 17Accolade: Turning Bullish After Beat-And-Raise Quarter (Rating Upgrade)
Jan 11Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge
Jun 13Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?
May 02An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued
Feb 05Accolade: Inching Closer To Profitability
Oct 17Accolade Q2 2023 Earnings Preview
Oct 05Accolade: Fair And Reasonably Priced, But Needs More Time
Aug 09Accolade Q1 2023 Earnings Preview
Jun 29Accolade: Little Recent Applause
Mar 28Accolade Impresses With Revenue Growth But Faces Operating Losses
Dec 16Accolade: I May Add To My Position
Oct 18Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 11Revenue & Expenses Breakdown
How Accolade makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Nov 24 | 447 | -180 | 166 | 92 |
31 Aug 24 | 441 | -80 | 166 | 96 |
31 May 24 | 432 | -89 | 165 | 99 |
29 Feb 24 | 414 | -100 | 162 | 99 |
30 Nov 23 | 388 | -123 | 163 | 98 |
31 Aug 23 | 380 | -142 | 167 | 99 |
31 May 23 | 371 | -155 | 170 | 98 |
28 Feb 23 | 363 | -460 | 175 | 99 |
30 Nov 22 | 358 | -464 | 188 | 98 |
31 Aug 22 | 350 | -401 | 189 | 97 |
31 May 22 | 336 | -417 | 190 | 95 |
28 Feb 22 | 310 | -123 | 186 | 84 |
30 Nov 21 | 275 | -93 | 138 | 75 |
31 Aug 21 | 230 | -132 | 110 | 65 |
31 May 21 | 194 | -85 | 78 | 55 |
28 Feb 21 | 170 | -51 | 63 | 50 |
30 Nov 20 | 156 | -48 | 57 | 45 |
31 Aug 20 | 147 | -50 | 57 | 43 |
31 May 20 | 140 | -49 | 56 | 42 |
29 Feb 20 | 133 | -51 | 56 | 42 |
30 Nov 19 | 123 | -56 | 55 | 43 |
28 Feb 19 | 95 | -56 | 43 | 36 |
28 Feb 18 | 77 | -61 | 43 | 31 |
Quality Earnings: ACCD is currently unprofitable.
Growing Profit Margin: ACCD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACCD is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.
Accelerating Growth: Unable to compare ACCD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACCD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.2%).
Return on Equity
High ROE: ACCD has a negative Return on Equity (-57.6%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/02 02:34 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/11/30 |
Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Accolade, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Matthew Gillmor | Baird |
Zhilin Long | Berenberg |
Allen Lutz | BofA Global Research |